Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Repurposing Ibrutinib for Chemo-Immunotherapy in a Phase 1b Study of Ibrutinib With Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients With Brain Cancer

NCT05106296 is registered in ClinicalTrials.gov with Theodore S. Johnson as lead sponsor.

NCT NCT05106296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05106296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Repurposing Ibrutinib for Chemo-Immunotherapy in a Phase 1b Study of Ibrutinib With Indoximod Plus Metronomic Cyclophosphamide and Etoposide for Pediatric Patients With Brain Cancer
Lead sponsor
Theodore S. Johnson
Phase
Phase 1
Overall status
Recruiting
Start date
February 8, 2022
Completion date
September 30, 2028
Enrollment
37 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ependymoma, glioblastoma, medulloblastoma, primary brain tumor